CAPTRUST Financial Advisors
IMDX

CAPTRUST Financial Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-225
Closed -$4K – 3375
2022
Q2 		$4K Hold
225
– – ﹤0.01% 4196
2022
Q1 		$7K Buy
+225
New +$7.19K ﹤0.01% 3982

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

CAPTRUST Financial Advisors's IMDX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 225 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in IMDX in Q1 2022 and held it in 2 quarters. The position peaked at $7K in Q1 2022. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 225 Insight Molecular Diagnostics shares in Q3 2022, an estimated $4K.
  • CAPTRUST Financial Advisors first reported a position in Insight Molecular Diagnostics in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Insight Molecular Diagnostics position peaked at $7K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.